Observational Study of Pergolide Mesylate and Cardiac Valvulopathy

Eli Lilly and Company200 enrolled

Overview

The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy. The secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Parkinson Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, age 18 and older with a diagnosis of Parkinson's Disease * Receiving pergolide as second-line therapy as prescribed by Summary of Product Characteristics * Willing to participate and sign a consent to release medical information * Have had an echocardiogram within 3 months of initiation of pergolide therapy with no evidence of cardiac valvulopathy Exclusion Criteria: * There are no exclusion criteria for this study

Locations (14)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Antwerp, Belgium

Edegem, Belgium

Ghent, Belgium

Montigny-le-Tilleul, Belgium

Wilrijk, Belgium

Aix-en-Provence, France

Clermont-Ferrand, France

Dijon, France

Montpellier, France

Strasbourg, France

...and 4 more locations